@inbook{3422d7a989ce4b6ab85cb9fa1f1d4370,
title = "Substance P-saporin for the treatment of intractable pain",
abstract = "Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P-Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing.We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP.",
keywords = "Allodynia, Hyperalgesia, NK1, Pain, SP-SAP, Substance P",
author = "Hugh Nymeyer and Lappi, {Douglas A.} and Denise Higgins and Noe, {Carl E.} and Frankel, {Arthur E.}",
note = "Funding Information: The authors would like to thank the University of Texas Southwestern Medical Center for financial support. Hugh Nymeyer would like to thank Tracy Nymeyer for her personal and financial support. Publisher Copyright: {\textcopyright} Springer International Publishing AG 2017.",
year = "2017",
doi = "10.1007/978-3-319-46877-8_6",
language = "English (US)",
series = "Milestones in Drug Therapy",
publisher = "Springer Basel",
pages = "107--130",
booktitle = "Milestones in Drug Therapy",
}